利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.027 秒)

    Hybrid polypeptides with selectable properties
    1.
    发明公开
    Hybrid polypeptides with selectable properties 有权
    杂交多肽mitauswählbarenEigenschaften

    公开(公告)号：EP2330124A2

    公开(公告)日：2011-06-08

    申请号：EP10012149.0

    申请日：2006-08-11

    申请人： Amylin Pharmaceuticals Inc.

    发明人： Levy, Odile Esther ,  Hanley, Michael R. ,  Jodka, Carolyn M. ,  Lewis, Diana ,  Soares, Christopher J. ,  Ghosh, Soumitra S. ,  D'Souza, Lawrence ,  Parkes, David G. ,  Mack, Christine M. ,  Forood, Behrouz Bruce

    IPC分类号： C07K14/575

    CPC分类号： C07K14/575 ,  A61K38/00 ,  C07K2319/00

    摘要： The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

    摘要翻译： 本发明一般涉及可用作治疗和预防代谢性疾病和病症的新型可选择的杂交多肽，所述代谢疾病和病症可以通过控制血浆葡萄糖水平，胰岛素水平和/或胰岛素分泌来减轻，例如糖尿病和糖尿病相关 条件。 这些病症和障碍包括但不限于高血压，血脂异常，心血管疾病，进食障碍，胰岛素抵抗，肥胖症和任何类型的糖尿病，包括1型，2型和妊娠糖尿病。

    Hybrid polypeptides with selectable properties
    4.
    发明公开
    Hybrid polypeptides with selectable properties 审中-公开
    具有可选特性的杂合多肽

    公开(公告)号：EP2330125A2

    公开(公告)日：2011-06-08

    申请号：EP10012633.3

    申请日：2006-08-11

    申请人： Amylin Pharmaceuticals, Inc.

    发明人： Levy, Odile Esther ,  Hanley, Michael R. ,  Jodka, Carolyn M. ,  Lewis, Diana ,  Soares, Christopher J. ,  Ghosh, Soumitra S. ,  D'Souza, Lawrence ,  Parkes, David G. ,  Mack, Christine M. ,  Forood, Behrouz Bruce

    IPC分类号： C07K14/575

    CPC分类号： C07K14/575 ,  A61K38/00 ,  C07K2319/00

    摘要： The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

    摘要翻译： 本发明一般涉及可用作治疗和预防可通过控制血浆葡萄糖水平，胰岛素水平和/或胰岛素分泌缓解的代谢疾病和病症的药剂的新型可选择杂合多肽，所述代谢疾病和病症例如糖尿病和糖尿病相关 条件。 这样的病症和障碍包括但不限于高血压，血脂异常，心血管疾病，进食障碍，胰岛素抵抗，肥胖和任何种类的糖尿病，包括1型，2型和妊娠糖尿病。

    Pancreatic polypeptide family motifs and polypeptides comprising the same
    6.
    发明公开
    Pancreatic polypeptide family motifs and polypeptides comprising the same 审中-公开
    胰腺POLYPEPTIDFAMILIENMOTIVE和含有多肽

    公开(公告)号：EP2335716A3

    公开(公告)日：2011-10-19

    申请号：EP10013143.2

    申请日：2005-02-11

    申请人： Amylin Pharmaceuticals Inc.

    发明人： Levy, Odile Esther ,  Jodka, Carolyn M. ,  Ghosh, Soumitra S. ,  Parkes, David G. ,  Pittner, Richard A. ,  D'Souza, Lawrence J. ,  Ahn, John S. ,  Prickett, Kathryn S.

    IPC分类号： A61K38/00 ,  C07K19/00 ,  C07K14/575

    CPC分类号： C07K14/575 ,  A61K38/00 ,  C07K14/475

    摘要： The present invention relates to novel Pancreatic Polypeptide Family ("PPF") polypeptides. The PPF polypeptides of the invention generally include at least two PPF motif, have at least 50 % sequence identity to PYY (3-36) over its length and will generally retain, at least in part, a biological activity of a PP, PYY or NPY Preferred PPF polypeptides of the invention are those having a potency in one of the assays described herein (preferably food intake, gastric emptying, pancreatic secretion, or weight reduction assays) which is greater than the potency of PP, NPY, PYY, or PYY(3-36) in that same assay. In one aspect, the PPF polypeptides of the invention include novel PYY analog polypeptides. In another aspect, the PPF polypeptides of the invention include PPF chimeric polypeptides including a fragment of a PP family polypeptide linked to a second PP family polypeptide, wherein each of the first and second fragments includes a PPF motif. Methods of using the PPF polypeptides of the invention, and pharmaceutical compositions including the PPF polypeptides of the invention are also disclosed.

    Pancreatic polypeptide family motifs and polypeptides comprising the same
    7.
    发明公开
    Pancreatic polypeptide family motifs and polypeptides comprising the same 审中-公开
    蛋白多糖多糖

    公开(公告)号：EP2335715A2

    公开(公告)日：2011-06-22

    申请号：EP10013127.5

    申请日：2005-02-11

    申请人： Amylin Pharmaceuticals Inc.

    发明人： Levy, Odile Esther ,  Jodka, Carolyn M. ,  Ghosh, Soumitra S. ,  Parkes, David G. ,  Pittner, Richard A. ,  D'Souza, Lawrence J. ,  Ahn, John S. ,  Prickett, Kathryn S.

    IPC分类号： A61K38/00 ,  C07K19/00 ,  C07K14/575

    CPC分类号： C07K14/575 ,  A61K38/00 ,  C07K14/475

    摘要： The present invention relates to novel Pancreatic Polypeptide Family ("PPF") polypeptides. The PPF polypeptides of the invention generally include at least two PPF motif, have at least 50 % sequence identity to PYY (3-36) over its length and will generally retain, at least in part, a biological activity of a PP, PYY or NPY Preferred PPF polypeptides of the invention are those having a potency in one of the assays described herein (preferably food intake, gastric emptying, pancreatic secretion, or weight reduction assays) which is greater than the potency of PP, NPY, PYY, or PYY(3-36) in that same assay. In one aspect, the PPF polypeptides of the invention include novel PYY analog polypeptides. In another aspect, the PPF polypeptides of the invention include PPF chimeric polypeptides including a fragment of a PP family polypeptide linked to a second PP family polypeptide, wherein each of the first and second fragments includes a PPF motif. Methods of using the PPF polypeptides of the invention, and pharmaceutical compositions including the PPF polypeptides of the invention are also disclosed.

    摘要翻译： 本发明涉及新型胰腺多肽家族（“PPF”）多肽。 本发明的PPF多肽通常包括至少两个PPF基序，其长度与PYY（3-36）具有至少50％的序列同一性，并且通常至少部分地保留PP，PYY的生物学活性或 NPY本发明优选的PPF多肽是在本文所述测定之一（优选食物摄取，胃排空，胰腺分泌或重量减轻试验）中具有效力的那些，其大于PP，NPY，PYY或PYY的效力 （3-36）。 一方面，本发明的PPF多肽包括新的PYY类似物多肽。 另一方面，本发明的PPF多肽包括PPF嵌合多肽，包括与第二PP家族多肽连接的PP家族多肽的片段，其中第一和第二片段中的每一个包括PPF基序。 还公开了使用本发明的PPF多肽的方法和包括本发明的PPF多肽的药物组合物。